Ozempic (semaglutide) can cause pancreatitis because it activates receptors on pancreatic cells that trigger cell growth and enzyme release, which in some people leads to inflammation of the pancreas. The FDA’s prescribing information carries a specific warning about acute pancreatitis, including fatal cases, and the risk appears highest in people who already have conditions that stress the pancreas.
How Ozempic Affects the Pancreas
Semaglutide works by mimicking a natural gut hormone called GLP-1, which helps regulate blood sugar and appetite. But GLP-1 receptors aren’t only in the gut and brain. They’re also found on the cells of the pancreas itself, and activating them sets off a chain of events that goes beyond insulin production.
When semaglutide binds to GLP-1 receptors on the enzyme-producing cells of the pancreas (called acinar cells), it triggers mild cell proliferation. Research published in Cell Reports showed that this growth comes with a side effect: as the cells multiply, they release more digestive enzymes. Importantly, the drug doesn’t directly force enzyme release the way a meal would. Instead, the enzymes leak out as a byproduct of the cells growing larger and dividing more than usual.
Over time, this overgrowth can increase the weight of the pancreas, block small ducts, and create localized inflammation. If the ducts become occluded, digestive enzymes that normally flow into the intestine can get trapped inside the pancreas, essentially causing the organ to start digesting itself. That’s pancreatitis.
Who Is Most at Risk
The biological mechanism matters, but it doesn’t affect everyone equally. Most people who take Ozempic never develop pancreatitis. The people who do tend to have pre-existing conditions that already put their pancreas under strain. Ironically, many of these are the same conditions Ozempic is prescribed to treat or that commonly accompany them.
- Obesity and visceral fat. Abdominal fat, regardless of overall BMI, has the greatest impact on pancreatitis risk. Fat can also accumulate directly inside the pancreas (pancreatic steatosis), creating chronic low-grade inflammation that primes the organ for an acute episode.
- Very high triglycerides. Triglyceride levels above 1,000 mg/dL, which are more common in people with obesity, can independently trigger acute pancreatitis.
- Gallstones. Changes in bile composition and how the gallbladder contracts can lead to gallstones, and GLP-1 drugs may further slow gallbladder motility. A stone blocking the shared duct between the gallbladder and pancreas is one of the most common causes of pancreatitis overall.
- Type 2 diabetes. Insulin resistance promotes ectopic fat deposits in the pancreas, liver, and heart. The resulting pancreatic inflammation creates a vulnerability that a drug-related trigger can push over the edge.
- Fatty liver disease (MAFLD). This condition is independently associated with a higher risk of acute pancreatitis, and it frequently coexists with obesity and diabetes.
- Smoking and alcohol use. Both are well-established pancreatitis risk factors on their own. Combined with semaglutide’s effects on pancreatic cells, they compound the danger. People with a history of heavy alcohol use are generally advised to stop drinking before starting GLP-1 therapy.
- Advanced kidney disease. Chronic kidney disease at stage 3 or higher was identified as a higher risk factor in analyses of pancreatitis cases among GLP-1 users.
How Common Is It
Pancreatitis from Ozempic is uncommon but not rare enough to ignore. An analysis of the FDA’s adverse event reporting system (FAERS) found 575 reports of pancreatitis linked to semaglutide, making up about 1% of all reported adverse events for the drug. That same analysis also detected a signal for pancreatic failure specifically with the injectable form, with a reporting odds ratio of 36.34, meaning it showed up far more often than would be expected by chance.
These numbers come with an important caveat: FAERS data captures reports, not confirmed diagnoses, and it can’t establish how many people took the drug without problems. But the signal is strong enough that both the FDA and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) have issued strengthened warnings. The FDA’s current label states that “acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide.”
Telling Pancreatitis Apart From Normal Side Effects
This is where things get tricky. Ozempic’s most common side effects are nausea, vomiting, and abdominal discomfort, which are also the early symptoms of pancreatitis. The MHRA specifically flagged this overlap, noting that pancreatitis “may be challenging to recognise in its early stages, as initial symptoms such as abdominal pain, nausea or vomiting may be attributed to other causes such as common gastrointestinal side effects.”
The key difference is severity, location, and persistence. Normal Ozempic side effects tend to be mild to moderate, come and go (often worsening after meals or dose increases), and improve over weeks as your body adjusts. Pancreatitis pain is different in several ways:
- Location: It centers in the upper abdomen, often in a band-like pattern, and frequently radiates straight through to the back.
- Intensity: The pain is severe and unrelenting. People often describe it as the worst abdominal pain they’ve ever felt.
- Duration: It doesn’t come in waves or settle after an hour. It persists and typically gets worse, not better, over time.
- Positioning: The pain often worsens when lying flat and may improve slightly when leaning forward.
If you experience severe abdominal pain that doesn’t let up, especially with vomiting, that warrants urgent medical evaluation regardless of whether you think it might just be a side effect.
How Pancreatitis Is Confirmed
Doctors diagnose acute pancreatitis when at least two of three criteria are present: upper abdominal pain, blood levels of a digestive enzyme called lipase that are more than three times the normal limit, and imaging showing pancreatic inflammation. Lipase is the preferred blood test because it’s more specific to the pancreas than the older amylase test.
One complication worth knowing about: diabetes itself can cause mildly elevated lipase levels even without pancreatitis. For that reason, some guidelines suggest that lipase needs to be three to five times the upper limit of normal, not just three times, to confidently make the diagnosis in people with diabetes. This means a single borderline blood test isn’t always definitive, and imaging with a CT scan or ultrasound often plays a deciding role.
If pancreatitis is confirmed while you’re on Ozempic, the standard approach is to stop the medication immediately. Most cases of acute pancreatitis resolve with supportive care over several days, but severe forms involving tissue death (necrotizing pancreatitis) or bleeding can be life-threatening and require hospitalization.
Reducing Your Risk
You can’t eliminate the risk entirely, but you can significantly reduce it by addressing the factors you control. Quitting smoking, avoiding alcohol, and managing triglyceride levels all lower the baseline stress on your pancreas. If you have symptoms of gallbladder disease (pain in the upper right abdomen after fatty meals, for example), getting an ultrasound before or shortly after starting Ozempic can catch gallstones early.
Paying attention to your body during dose increases is also practical. Most pancreatitis cases with GLP-1 drugs appear to occur relatively early in treatment or after a dose escalation, when drug levels in the body are climbing. The gradual dose-titration schedule that Ozempic uses (starting low and increasing monthly) exists partly to minimize this kind of risk. Skipping ahead or accelerating the schedule removes that safety buffer.